MedTrace Logo

Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

NCT05594342 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-10-26

No results posted yet for this study

Summary

Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF requiring inotropic support is limited to case series.1 This study aimed to evaluate ivabradine safety and tolerability in admitted cardiogenic shock patients who started on dobutamine infusion for inotropic support.

Conditions

Interventions

DRUG

Ivabradine 7.5Mg Tab

Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.

DRUG

DOBUTamine Injectable Solution

Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute

Sponsors & Collaborators

  • The Young Investigator Group of Cardiovascular Research

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05594342 on ClinicalTrials.gov